Drug Release Kinetics Research Articles

In vitro kinetics characterisation of polymeric nanoparticles for anticancer therapy

World Health Organization (WHO) predicts that cancer incidence will increase in the future, thus research involving anticancer agents such as nanoparticles has gained significant importance. Nanoparticles can be made from various materials, but the focus on polymeric chitosan and/or carrageenan-based nanoparticles is significant. Research on these materials investigates dynamic parameters of in vitro drug release, stability under working conditions and stability under storage conditions (in vitro kinetics characterisations). Here, a literature review is conducted to provide in-depth insights on research methodology trends, drawbacks, suitability, suggestions for improvements and findings related to polymeric carrageenan and/or chitosan nanoparticles for anticancer therapy. Journal articles involving nanoparticles made from chitosan and/or carrageenan containing anticancer agents published between 2017 and 2022 were acquired through Google Scholar search using relevant keywords. Generally, the methods used to investigate drug release kinetics of nanoparticles can be categorised into dialysis membrane, sample and separate or direct measurement methods. Studies on the response of physiochemical characteristics towards changes in environment do not vary highly and are generalisable. Stability studies primarily measure the physicochemical changes of nanoparticles as a response measurement towards storage conditions. Both drug release selectivity and physicochemical characteristics response in different pH environments were found to be predictable via the ionisation of polymers and drugs used in different pH. The size of the nanoparticles formed during polyelectrolyte complexation process was found to be at its minimum at a balanced pH, possibly due to increased polymer-polymer attraction. The methods used for in vitro kinetics studies were generalised, and suggestions to address potential sources of errors were given in the current review. The selectivity of drug release and changes in physicochemical characteristics of the nanoparticles in different pH environments were found to largely coincide with the principles of ionisation of nanoparticle constituent.

Capecitabine-loaded NLC for Breast Cancer Treatment: Preparation, Characterization, and In vitro Evaluation.

Cancer treatment often involves the use of potent antineoplastic drugs like Capecitabine [CAP], which can lead to serious toxicities. There is a need for dosage forms to manage these toxicities that can deliver the medication effectively to the target site while maintaining therapeutic efficacy at lower doses. To achieve the aforesaid objective, NLC containing capecitabine [NANOBIN] was prepared and evaluated. Different formulations of NANOBIN, denoted as CaTS, CaT1S, CaT2S, CaTS1, and CaTS2, were designed and evaluated to improve drug delivery and therapeutic outcomes. The NANOBIN formulations were prepared using the hot homogenization method. The characterization of these formulations was conducted based on various parameters such as particle size, Polydispersity Index [PDI], Zeta Potential [ZP], Transmission Electron Microscopy [TEM] imaging, and Encapsulation Efficiency [EE]. In vitro evaluations included stability testing, release studies to assess drug release kinetics, and a cytotoxicity assay [MTT assay] to evaluate the efficacy of these formulations against human breast cancer cells [MCF-7]. The characterization results revealed that all NANOBIN formulations exhibited particle sizes ranging from 65 to 193 nm, PDI values within the range of 0.26-0.37, ZP values between 46.47 to 61.87 mV [-ve], and high EE percentages ranging from 94.121% to 96.64%. Furthermore, all NANOBIN formulations demonstrated sustained and slow-release profiles of CAP. The MTT assay showed that the NANOBINs exhibited significantly enhanced cytotoxic efficacy, approximately 10 times greater than free CAP when tested on MCF-7 cells. These findings indicate the potential of NANOBINs to deliver CAP effectively to the target site, enabling prolonged drug availability and enhanced therapeutic effects at lower doses. The study demonstrates that NANOBINs can effectively deliver CAP to target sites, prolonging drug exposure and enhancing therapeutic efficacy while reducing the required dose. Further studies are necessary to validate these findings and establish NANOBINs as a preferred treatment option for cancer therapy.

Preparation and Characterization of Oxide Nanotubes on Titanium Surface for Use in Controlled Drug Release Systems.

Preventing or treating infections at implantation sites where the risk of bacterial contamination is high requires the development of intelligent drug delivery systems. The objective of this work was to develop a production method and characterization of fourth-generation oxide nanotubes on titanium grade 4 surface as a potential drug carrier. This study focused on the anodizing process; physico-chemical characterization using FE-SEM, EDS, and FTIR; in vitro corrosion resistance in an artificial saliva solution; and determining the drug release kinetics of gentamicin sulfate using UV-VIS. The anodizing process was optimized to produce fourth-generation oxide nanotubes in a fluoride-free electrolyte, ensuring rapid growth and lack of order. Results showed that the length of the oxide nanotubes was inversely proportional to the anodizing voltage, with longer nanotubes formed at lower voltages. The nanotubes were shown to have a honeycomb structure with silver particles co-deposited on the surface for antibacterial properties and were capable of carrying and releasing the antibiotic gentamicin sulfate in a controlled manner, following Fick's first law of diffusion. The corrosion resistance study demonstrates that the oxide nanotubes enhance the corrosion resistance of the titanium surface. The oxide nanotubes show promise in enhancing osseointegration and reducing post-implantation complications.

Polyurea-urethane Temperature-responsive Hydrogels for Sustained Delivery of Anti-VEGF Therapeutics.

Temperature-responsive hydrogels, or thermogels, have emerged as a leading platform for sustained delivery of both small molecule drugs and macromolecular biologic therapeutics. Although thermogel properties can be modulated by varying the polymer's hydrophilic-hydrophobic balance, molecular weight and degree of branching, varying the supramolecular donor-acceptor interactions on the polymer remains surprisingly overlooked. Herein, to study the influence of enhanced hydrogen bonding on thermogelation, we synthesized a family of amphiphilic polymers containing urea and urethane linkages using quinuclidine as an organocatalyst. Our findings showed that the presence of strongly hydrogen bonding urea linkages significantly enhanced polymer hydration in water, in turn affecting hierarchical polymer self-assembly and macroscopic gel properties such as sol-gel phase transition temperature and gel stiffness. Additionally, analysis of the sustained release profiles of Aflibercept, an FDA-approved protein biologic for anti-angiogenic treatment, showed that urea bonds on the thermogel were able to significantly alter the drug release mechanism and kinetics compared to usage of polyurethane gels of similar composition and molecular weight. Our findings demonstrate the unrealized possibility of modulating gel properties and outcomes of sustained drug delivery through judicious variation of hydrogen bonding motifs on the polymer structure.

Preparation and performance evaluation of fast dissolving polymer microneedles piggybacked with sitagliptin

The dramatic rise in the number of obese/overweight people is a global public health challenge that urgently requires novel and effective therapies. In this study, we designed a fast dissolving polymer microneedle array patch (SGN-PVP/PVA-MN) with sitagliptin as a model drug for treating obesity, focusing on the preparation process of the patch. We then characterized the morphology and dimensions of SGN-PVP/PVA-MN. Furthermore, we delved into the mechanical properties, solubility, skin-puncturing capability, and transdermal drug diffusion and release kinetics of SGN-PVP/PVA-MN. The results demonstrated that SGN-PVP/PVA-MN exhibited favorable morphology and mechanical properties, effectively penetrating the stratum corneum and creating microchannels for rapid transdermal drug diffusion. The in vitro transdermal diffusion assays revealed the release of 64.5% of the drug within 2 min and 95.7% within 10 min. With rapid dissolution and high drug diffusion efficiency, SGN-PVP/PVA-MN is poised to serve as an effective and safe treatment option for the individuals with obesity.

Development of sinomenine hydrochloride loaded shell/core nanofibrous with pH‐responsive for colon‐targeted drug delivery

AbstractA series of colon‐targeted, sustained‐release, sinomenine hydrochloride (SH) loaded shell/core electrospun nanofibers are reported. The fibers have shells made of Eudragit S100 (ES‐100), and drug‐loaded cores comprising of Eudragit RS100 (ERS‐100) and SH. The essential characteristics of membranes are evaluated by scanning electron microscopy, transmission electron microscope, Fourier transformed infrared spectroscopy, and x‐ray diffraction. In vitro release of SH show that the shell/core nanofiber membranes can block drug release in the HCl buffer (pH 1.2), and the release time of the hydrophilic drug SH exceed 240 min at pH 7.4 phosphate buffer solution. In vitro drug release kinetics consistent with the first‐order model. The shell/core nanofiber can achieve colon‐targeted and sustained‐release properties, which can better prevent the loss of SH and relieve the adverse effects on gastrointestinal tract. In addition, the hemolysis and cytotoxicity tests manifest that the nanofiber membrane display good hemocompatibility and cytocompatibility. These results suggest the SH‐containing nanofiber membranes have potential applications as a colon‐targeted drug delivery system that sustained release. They also offer a theoretical foundation for the development of novel dosage forms for SH.

Engineering of Erythrocytes as Drug Carriers for Therapeutic Applications.

Erythrocytes, also known as red blood cells (RBCs), have garnered considerable attention as potential carriers for drug delivery, owing to their inherent properties such as biocompatibility, biodegradability, and prolonged circulation half-life. This paper presents a comprehensive overview of the role of erythrocytes in drug delivery, elucidating recent advancements in delivering a diverse array of therapeutic agents, including small molecules, nucleic acids, antibodies, protein enzymes, and nanoparticles. Two primary strategies for encapsulating drugs within erythrocytes are systematically discussed: internal loading and surface loading. Each strategy offers distinct advantages in terms of drug stability and release kinetics. Notably, the utilization of erythrocyte membrane camouflaged nanocarriers holds promise for enhancing the biocompatibility of conventional nanoparticles and facilitating targeted drug delivery. Furthermore, the broad spectrum of biomedical applications of erythrocyte-based drug delivery systems are examined, ranging from cancer treatment to diabetes management, thrombosis prevention, and immunotherapy. This review provides a comprehensive evaluation of current technologies in erythrocyte-loaded drug delivery, highlighting the strengths, weaknesses, and future directions for advancing therapeutic interventions in various disease contexts.

An Overview of Novel Drug Delivery Systems for Cardiovascular Diseases Application

Progress in nanotechnology and immunotherapy has facilitated the development of drugloaded nanocarriers through encapsulation techniques that are aimed at treating cardiovascular disease (CVD). While these drug delivery systems have exhibited promising outcomes, several clinical limitations necessitate identification and resolution. This overview emphasizes novel drug delivery systems, particularly ghost stents, mesenchymal extracellular vesicles, microbubble therapy, and aptamers, tailored for CVD management. Moreover, we explore the drug release kinetics associated with these systems to discern their release profiles in human blood, operating on specific stimuli to maintain stable plasma drug concentrations. Presently, advanced drug delivery modalities such as polymeric nanoparticles, natural metallic nanoparticles, aptamers, microbubbles, exosomes, polymeric micelles, and drug-eluting stents are employed in CVD treatment. These systems effectively circumvent immune responses and enhance the quality of life for patients with cardiovascular disorders, thereby improving patient adherence and treatment efficacy. The described systems offer a promising avenue for drug delivery, presenting a potential strategy to enhance the efficacy of current therapies.

Lignin‐based polyurethane composites enhanced with hydroxyapatite for controlled drug delivery and potential cellular scaffold applications

AbstractPolymer technology has rapidly advanced across diverse domains, particularly in biomedical applications. Among various polymers, polyurethane (PU) hold great potential in developing biomaterials such as biomedical scaffold and drug delivery. In this study, we have innovatively engineered eco‐friendly polyurethane using lignin, a sustainable bio‐polyol derived from oil palm empty fruit bunches. To enhance the physicochemical properties of the PU, we have incorporated hydroxyapatite (HA) into the composites. The inclusion of HA has led to notable improvements in crucial properties such as density, porosity, and water absorption, making these composites ideal candidates for tissue regeneration scaffolds. Furthermore, to assess their biomedical applicability in drug delivery and cell scaffolding, we have employed the quercetin drug model. The results revealed a sustained kinetic release behavior within the polyurethane/hydroxyapatite (PU/HA) composites, showcasing their potential for controlled drug delivery applications. Moreover, cytotoxicity assays conducted using neuro‐2a cell models demonstrated the non‐cytotoxic nature of both PU and PU/HA composites. This finding holds significant implications for biomedical applications, indicating that these composites offer biocompatible platforms for tissue engineering and regenerative medicine endeavors. The ability of these composites to support cell viability underscores their potential for a wide range of biomedical applications, including neural tissue engineering and drug delivery systems targeting brain diseases. These findings pave the way for the development of innovative and sustainable biomaterials with diverse biomedical applications.Highlights An eco‐friendly polyurethane has been engineered by harnessing liginin‐derived oil palm empty fruit bunches. Incorporation of hydroxyapaptite enhance the physical properties of polyurethane. Controlled kinetic drug release is one of polyurethane/hydroxyapatite (PU/HA) composites features. The PU/HA composites has low cytotoxicity against neuro‐2a cells.

Cutting-Edge Developments and Patent Trends in Microspheres Drug Delivery: A Comprehensive Overview.

Microspheres have emerged as innovative drug delivery platforms with significant potential to improve the therapeutic efficacy of drugs with limited aqueous solubility and prolong their release. This abstract provides an overview of recent developments in microsphere research, highlighting key trends and innovative approaches. Recent studies have focused on various aspects of microspheres, including formulation techniques, materials selection, and their applications in drug delivery. Recent breakthroughs in polymer science have paved the way for the creation of innovative biodegradable and biocompatible materials for microsphere fabrication, improving drug encapsulation effectiveness and release dynamics. Notably, the integration of nanomaterials and functionalized polymers has enabled precise control over drug release rates and enhanced targeting capabilities. The utilization of microspheres for administering a diverse array of therapeutic substances, including anticancer drugs, anti-inflammatory agents, and peptides, has gained significant attention. These microspheres have demonstrated the potential to enhance drug stability, minimize dosing frequency and enhance patient adherence.

Impact of PEG Content on Doxorubicin Release from PLGA-co-PEG Nanoparticles.

Nanoparticles (NPs) have become attractive vehicles for drug delivery in cancer therapy due to their ability to accumulate in tumours and mitigate side effects. This study focuses on the production of doxorubicin (DOX)-loaded NPs comprising Poly (lactic-co-glycolic acid)-Polyethylene glycol with varying PEG proportions and the examination of their impact on drug release kinetics. DOX-loaded NPs, composed of PLGA-co-PEG with PEG contents of 0%, 5%, 10%, and 15%, were synthesized by the solvent evaporation technique, exhibited spherical morphology, and had sizes ranging from 420 nm to 690 nm. In vitro drug release studies revealed biphasic profiles, with higher PEG contents leading to faster and more extensive drug release. The Baker-Lonsdale model demonstrated the best fit to the drug release data, indicating that the release process is diffusion-controlled. The diffusion coefficients for DOX determined ranged from 6.3 × 10-18 to 7.55 × 10-17 cm2s-1 and exhibited an upward trend with increasing PEG content in the polymer. In vitro cytotoxicity tests with CHO cells showed that unloaded NPs are non-toxic, while DOX-loaded PLGA-PEG 15% NPs induced a greater decrease in cellular viability compared to their PLGA counterparts. A mathematical relationship between the diffusion coefficient and PEG percentage was derived, providing a practical tool for optimizing DOX release profiles.

Nano/genetically engineered cells for immunotherapy

AbstractImmunotherapy has recently emerged as a promising therapeutic modality for the treatment of various diseases such as cancer, inflammation, autoimmune diseases, and infectious diseases. Despite its potential, immunotherapy faces challenges related to delivery efficiency and off‐target toxicity of immunotherapeutic drugs. Nano drug delivery systems offer improvements in drug biodistribution and release kinetics but still suffer from shortcomings such as high immunogenicity, poor penetration across biological barriers, and insufficient tissue permeability. Targeted delivery of drugs using living cells has become an emerging strategy that can take advantage of the inherent characteristics of cells to deal with the delivery defects of nano delivery systems. Furthermore, cells themselves can be genetically engineered into cellular drugs for enhanced immunotherapy. This review provides an in‐depth exploration of cell‐derived drug carriers, detailing their biological properties, functions, and commonly used drug loading strategies. In addition, the role of genetically modified cells in immunotherapy and their synergistic therapeutic effects with drug delivery are also introduced. By summarizing the main advancements and limitations in the field, this review offers insights into the potential of cell‐based drug delivery systems to address the existing challenges in immunotherapy. The introduction to recent developments and evaluation of ongoing research will pave the way for the optimization and widespread adoption of nano/genetically engineered cells for immunotherapy.

Optimization and evaluation of modified release solid dosage forms using artificial neural network

This study aims to optimize and evaluate drug release kinetics of Modified-Release (MR) solid dosage form of Quetiapine Fumarate MR tablets by using the Artificial Neural Networks (ANNs). In training the neural network, the drug contents of Quetiapine Fumarate MR tablet such as Sodium Citrate, Eudragit® L100 55, Eudragit® L30 D55, Lactose Monohydrate, Dicalcium Phosphate (DCP), and Glyceryl Behenate were used as variable input data and Drug Substance Quetiapine Fumarate, Triethyl Citrate, and Magnesium Stearate were used as constant input data for the formulation of the tablet. The in-vitro dissolution profiles of Quetiapine Fumarate MR tablets at ten different time points were used as a target data. Several layers together build the neural network by connecting the input data with the output data via weights, these weights show importance of input nodes. The training process optimises the weights of the drug product excipients to achieve the desired drug release through the simulation process in MATLAB software. The percentage drug release of predicted formulation matched with the manufactured formulation using the similarity factor (f2), which evaluates network efficiency. The ANNs have enormous potential for rapidly optimizing pharmaceutical formulations with desirable performance characteristics.

Nanoparticle-based targeted therapy through EGFR tyrosine kinase inhibitors and their recent advances in lung cancer therapy

The emergence and subsequent advancement of nanotechnology in recent years have greatly benefited the healthcare sector, particularly in the treatment of cancer. As per study, major fatalities are related to the lung cancer. For many years, oral tyrosine kinase inhibitors (TKIs) against the epidermal growth factor receptor (EGFR) family of receptors have been used in the clinic to treat human malignancies, although they observed some very serious adverse effects in the treatment of lung cancer, especially in non-small cell lung cancer (NSCLC). Despite EGFR-TKIs’ exceptional qualities as small-molecule targeted medications, their applicability is nevertheless limited by their poor solubility, inconsistent oral bioavailability, high daily dose needs, high plasma albumin binding propensity, and initial/acquired drug resistance. Article’s purpose is to investigate EGFR-TKI’s effects on lung cancer and get around some of its drawbacks, nanotechnology will be an innovative strategy. An effective tool to increase the effectiveness of these pharmaceuticals is nanotechnology by methods other than oral. This article signifies that a range of nanomedicine delivery systems have been developed to effectively distribute EGFR-TKIs with improved drug release kinetics and tissue-targeting capacity. This review article intends to present information regarding lung cancer and EGFR relation, mechanism of recently approved EGFR-TKI’s targeted therapy, an updated landscape of EGFR-TKIs and their clinical status over lung cancer, advantages and disadvantages of nanotechnology, and new breakthroughs in nano-delivery which mentioned as a significantly better over traditional drug chemotherapy and delivery.

ZIF-8-mediated block copolymer micelles and its application in drug delivery

Block copolymer micelles have been widely used in drug delivery. Great efforts have been made to optimize the function of block copolymer micelles and further enhance their bioavailability. We propose a means of embedding ZIF-8 in block copolymer micelles to regulate its stability for improving the drug release kinetics. The block copolymer poly (2-(diisopropyl amino-ethyl methacrylate)-block-poly (vinylimidazole-co-poly (ethylene glycol) methyl methacrylate) (PDPA18-b-P(Vim18-co-P(EG)5MA21) (PDPV) bearing imidazole moiety was synthesized through reversible addition-cracking chain transfer (RAFT) polymerization. PDPV can self-assemble into micelles in aqueous solution and then be loaded with doxorubicin (DOX) to obtain DOX@PDPV, followed by Zn coordination to anchor ZIF-8 to the PVim moiety in DOX@PDPV to obtain the final drug delivery system DOX@PDPV@ZIF-8 hybrids. The DOX@PDPV@ZIF-8 hybrids can avoid the influence of the critical micelle concentration (CMC) on it, which was further prevent the premature leakage of DOX under physiological conditions. Furthermore, the pH-responsive properties of PDPA and ZIF-8 facilitated enabled the effective release of DOX in weakly acidic tumor environments. In vitro studies also confirmed that DOX@PDPV@ZIF-8 improved DOX accumulation in cells, leading to the inhibition of cancer cell growth. Therefore, the integrated design provided a promising strategy to regulate the stability of block copolymer micelles, improve drug release kinetics, and ultimately inhibit the growth of cancer cell.

Harnessing Potential of ω-3 Polyunsaturated Fatty Acid with Nanotechnology for Enhanced Breast Cancer Therapy: A Comprehensive Investigation into ALA-Based Liposomal PTX Delivery.

Our hypothesis posited that incorporating alpha-linolenic acid (ALA) into liposomes containing Paclitaxel (PTX) could augment cellular uptake, decrease the therapeutic dosage, and alleviate PTX-related side effects. Our investigation encompassed characterization of the liposomal formulation, encompassing aspects like particle size, surface morphology, chemical structure, drug release kinetics, and stability. Compatibility studies were performed through Fourier transform infrared spectroscopy (FTIR). By utilizing the Box-Behnken design (BBD), we developed ALA-based liposomes with satisfactory particle size and entrapment efficiency. It is noteworthy that ALA incorporation led to a slight increase in particle size but did not notably affect drug entrapment. In vitro drug release assessments unveiled a sustained release pattern, with ALA-PTX liposomes demonstrating release profiles comparable to PTX liposomes. Morphological examinations confirmed the spherical structure of the liposomes, indicating that substituting ALA with phosphatidylcholine did not alter the physicochemical properties. Cellular uptake investigations showcased enhanced uptake of ALA-based liposomes in contrast to PTX liposomes, likely attributed to the heightened fluidity conferred by ALA. Efficacy against MCF-7 cells demonstrated concentration-dependent reductions in cell viability, with ALA-PTX liposomes exhibiting the lowest IC50 value. Morphological analysis confirmed apoptotic changes in cells treated with all formulations, with ALA-PTX liposomes eliciting more pronounced changes, indicative of enhanced anticancer efficacy.

Kinetic study of in vitro release of curcumin from chitosan biopolymer and the evaluation of biological efficacy

Sustained release of curcumin from the polymeric carrier system chitosan, a natural biopolymer material derived from chitin originated from natural shrimp shell waste, was studied. Six kinetic models, zero order, first order, Korsmeyer–Peppas (KP), Peppas – Sahlin (PS), Higuchi, and Hixson–Crowell, were applied to study the drug release kinetics. The release mechanism of the drug from the curcumin-chitosan composite was evaluated by changing the pH, ionic strength of the release media, and drug concentration. KP and PS models were selected among the studied models to investigate the drug release mechanism from the chitosan biopolymer based on the R2 values (R2 > 0.99). The model constants m in the PS model and n in the KP model stand for the case II relaxation and Fickian diffusion contribution, respectively. The n being < 0.43 in the KP model suggests that the Fickian diffusion governs the drug release. Furthermore, there is a noticeable difference between the values obtained for model parameters m and n in the PS and KP models, indicating that Case II relaxation and Fickian diffusion play crucial roles in the curcumin release mechanism from chitosan. Polymer relaxation has been proven to play a predominant role in releasing curcumin from the composite at lower ionic strengths and higher pH values. Anti-inflammatory activity was tested using the egg-albumin denaturation assay, and the diphenyl-2-picrylhydrazyl assay was carried out to determine the antioxidant activity of the composite. The composite material showed IC50 values of 0.29 mg/ mL and 1.08 mg/ mL for anti-inflammatory and anti-oxidant activities, respectively. The drug composite has shown antibacterial activity against Pseudomonas aeruginosa, Klebsiella pneumoniae, and Staphylococcus aureus, which are highly effective against S.aureus. The resulting inhibition zones for S.aureus were 13.34 ± 0.34 mm, 16.34 ± 0.60 mm, and 13.34 ± 0.73 mm for 5, 10, and 20 mg/ml concentrations, respectively. The drug composite’s minimum inhibitory concentration/ minimum bactericidal concentration ratio for S.aureus, K. pneumoniae, and P.aeruginosa was greater than 4, suggesting that they cause bacteriostatic effects.

In-vitro and in-vivo investigation of wound healing efficacy of Syzygium cumini leaf extracts loaded carboxymethylcellulose film

The study focused on Syzygium cumini Leaf Extract (SCLE) loaded into Carboxymethylcellulose (CMC) film via Solution casting. Phytochemical screening revealed carbohydrates, and HPLC analysis identified quercetin, known for promoting wound healing. FT-IR spectroscopy confirmed various functional groups. X-Ray diffraction (XRD) determined the crystallite size to be 14.58 nm. Field Emission Scanning Electron Microscopy (FESEM) showed the dispersion of extracts, and Energy Dispersive X-ray (EDX) analysis detailed the weight percentages of components. Antibacterial activity tests revealed zones of inhibition for S. aureus (15 mm) and E. coli (11 mm). The film exhibited 63.11 % antioxidant activity at 517 nm with DPPH at a 750 μl sample concentration. Drug release kinetics were also studied. In-vitro wound healing using the L929 cell line showed 83 % healing at a 100 μl concentration. Over 14 days, the treatment group's wounds healed completely within 7 days, unlike the control groups which showed no recovery after 14 days. These findings indicate that the SCLE-CMC film is highly effective in promoting wound healing.

Modulation of mechanical properties of low molecular weight supramolecular hydrogels of calcium cholate by drugs of varying hydrophobicity: Effect on drug release, antioxidant, and antibacterial properties

Bile salt based low-molecular-weight supramolecular hydrogels (LMWSH) serve as an appealing framework for drug delivery applications, owing to their natural origin, biocompatibility, and the peculiar distribution of hydrophobic and hydrophilic domains. In this work, LMWSH based on an ionotropic gel of sodium cholate assisted by Ca2+ ions (CaC) was developed as a drug delivery system for both hydrophilic and hydrophobic drugs. Diosgenin, Quercetin, Rutin, and Amygdalin were chosen as model drugs, having varying hydrophobicity. The mechanical strength of the CaC hydrogel is enhanced by increasing the hydrophobicity of the loaded drug. The close-knit mesh design of CaC hydrogels loaded with hydrophobic drugs resulted in controlled drug release compared to the hydrophilic drugs. Drug-loaded CaC hydrogels exhibited good swelling and thixotropy, making them suitable for injectable formulations. In kinetic drug release, both relaxation and diffusion mechanisms play a pivotal role. The antioxidant and antibacterial activity of the loaded drugs increased synergistically in the hydrogels. Thus, due to these properties, the hydrogels can be safely used as topical gels against wound healing. This study shows that bile salts exhibit potential to enhance the delivery of both hydrophobic and hydrophilic drugs, making them promising candidates for biomedical applications.

Development of rosuvastatin calcium nano-carrier patches by central composite design

Rosuvastatin (RS) is a statin medication used to lower cholesterol levels and reduce the risk of cardiovascular diseases. RS works by inhibiting an enzyme called HMG-CoA reductase, which helps decrease LDL cholesterol and increase HDL cholesterol. The typical dose range for rosuvastatin is 5-40 mg once daily, with the starting dose usually being 10 mg. However, the dosage may vary depending on the patient's cholesterol levels and individual response to the medication. Rosuvastatin has a half-life of approximately 19 hours and undergoes metabolism mainly in the liver. The aim of the study was to develop a transdermal patch containing Rosuvastatin in the form of niosomes (NP). The Rosuvastatin niosomes were prepared using the solvent casting method, and the optimized formulation showed a particle size of 211.6 nm with a polydispersity index (PDI) of 0.197. The zeta potential of the niosomes was found to be -44.7. These results indicate that the developed formulation has a uniform particle size distribution and a stable zeta potential, which are important factors for the effective delivery of Rosuvastatin through a transdermal patch. Invitro diffusion studies of the optimized patch RN-T6 released upto 24 hours with %CDR of 98.98% and the drug diffusion data is fitted into various mathematical models and RN-T6 followed zero order drug release kinetics and the diffusion mechanism was non-fickian diffusion.